However, guidelines recommend several drug classes that can temporarily improve some symptoms, including the following: acetylcholinesterase inhibitors such as donepezil, galantamine (razadyne), and rivastigmine, memantine, monoamine oxidase type B inhibitor (Selegiline), and antipsychotics such as olanzapine and risperidone (however, they are still not approved by the U.S. Food and Drug Administration for the treatment of Alzheimer's disease) [38]–[40]. This evidence concerns the gene MAOB and early-onset autosomal dominant Alzheimer disease.